Combination strategies surely play a crucial role in treatment of cancer. Stereotactic ablative radiotherapy (SABR) has been described to induce abscopal effects particularly in renal cell cancer metastases. This effect is a reaction induced following irradiation of tumour tissue and occurring in another metastatic location outside the treatment field. However, this effect is limited and occurs sparsely in about 1-5% of patient. We are planning to improve the clinical outcome of this treatment in metastatic solid tumours by combining SABR with sequential immunotherapeutic treatments including vaccination strategies, adoptive cell therapy, cytokine therapy, or anti-CTLA-4 therapy. © 2012 Masucci et al.; licensee BioMed Central Ltd.
CITATION STYLE
Masucci, G. V., Wersäll, P., Kiessling, R., Lundqvist, A., & Lewensohn, R. (2012, May 22). Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-10-104
Mendeley helps you to discover research relevant for your work.